Literature DB >> 16227639

Lipoic acid - the drug of the future?

Anna Bilska1, Lidia Włodek.   

Abstract

Numerous experimental and clinical studies proved efficiency of treatment with lipoic acid-containing drugs in diseases, in which pro- and antioxidant balance is disrupted (diabetes, neurodegenerative diseases, acquired immune deficiency syndrome (AIDS), tumors, etc.). Efficiency of lipoate has been attributed to unique antioxidant properties of lipoate/dihydrolipoate system, its reactive oxygen species (ROS) scavenging ability and significant effect on the tissue concentrations of reduced forms of other antioxidants, including one of the most powerful, glutathione (thus lipoate is called an antioxidant of antioxidants). Moreover, analysis of literature data suggests participation of lipoic acid in processes of cell growth and differentiation. This fact can be crucial to clinical practice, however, this problem requires further studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227639

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  78 in total

1.  Development of fatty acid-producing Corynebacterium glutamicum strains.

Authors:  Seiki Takeno; Manami Takasaki; Akinobu Urabayashi; Akinori Mimura; Tetsuhiro Muramatsu; Satoshi Mitsuhashi; Masato Ikeda
Journal:  Appl Environ Microbiol       Date:  2013-08-30       Impact factor: 4.792

2.  Critical Role of Macrophage FcγR Signaling and Reactive Oxygen Species in Alloantibody-Mediated Hepatocyte Rejection.

Authors:  Jason M Zimmerer; Xin L Liu; Alecia Blaszczak; Christina L Avila; Thomas A Pham; Robert T Warren; Ginny L Bumgardner
Journal:  J Immunol       Date:  2018-11-05       Impact factor: 5.422

3.  Uptake and reduction of alpha-lipoic acid by human erythrocytes.

Authors:  James M May; Zhi-chao Qu; Deanna J Nelson
Journal:  Clin Biochem       Date:  2007-07-05       Impact factor: 3.281

4.  Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid.

Authors:  Uracha Ruktanonchai; Piyawan Bejrapha; Usawadee Sakulkhu; Praneet Opanasopit; Nuntavan Bunyapraphatsara; Varaporn Junyaprasert; Satit Puttipipatkhachorn
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

5.  Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes.

Authors:  Sahar K Hegazy; Osama A Tolba; Tarek M Mostafa; Manal A Eid; Dalia R El-Afify
Journal:  Rev Diabet Stud       Date:  2013-05-10

6.  Efficacy of Alpha-lipoic Acid in The Management of Diabetes Mellitus: A Systematic Review and Meta-analysis.

Authors:  Mahmoud Ahmed Ebada; Notila Fayed; Laila Fayed; Souad Alkanj; Ahmed Abdelkarim; Haya Farwati; Aya Hanafy; Ahmed Negida; Mohamed Ebada; Yousef Noser
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

7.  Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?

Authors:  Márcia Calheiros Chaves Silva; Caren Nádia Soares de Sousa; Luis Rafael Leite Sampaio; Naiara Coelho Ximenes; Paulo Victor Pontes Araújo; Jéssica Calheiros da Silva; Suzyana Lima de Oliveira; Francisca Cléa Florenço Sousa; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-16       Impact factor: 3.000

8.  Alpha-lipoic acid improves acetic acid-induced gastric ulcer healing in rats.

Authors:  Berna Karakoyun; Meral Yüksel; Feriha Ercan; Can Erzik; Berrak C Yeğen
Journal:  Inflammation       Date:  2009-02       Impact factor: 4.092

9.  Redox homeostasis of albumin in relation to alpha-lipoic acid and dihydrolipoic acid.

Authors:  Pinar Atukeren; Seval Aydin; Ezel Uslu; M Koray Gumustas; Ufuk Cakatay
Journal:  Oxid Med Cell Longev       Date:  2010 May-Jun       Impact factor: 6.543

10.  Prophylaxis with alpha-lipoic acid against lipopolysaccharide-induced brain injury in rats.

Authors:  Anna Goraca; Katarzyna Asłanowicz-Antkowiak
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-03-31       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.